Biologic Therapy for Psoriatic Arthritis

Rheumatic Disease Clinics of North America

Volumn 41, Issue 4, 2015, Pages 723-738

  Mease, Philip J ^a,b  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Biologics; IL 12 23 inhibition; IL 17 inhibition; IL 23 inhibition; Psoriasis; Psoriatic arthritis; TNF inhibition

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; BRODALUMAB; CERTOLIZUMAB; CLAZAKIZUMAB; ETANERCEPT; GOLIMUMAB; GUSELKUMAB; INFLIXIMAB; IXEKIZUMAB; METHOTREXATE; PLACEBO; RITUXIMAB; SECUKINUMAB; TILDRAKIZUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; ARTHRITIS; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CELL SPECIFICITY; CLINICAL DECISION MAKING; COST BENEFIT ANALYSIS; COST CONTROL; DACTYLITIS; DERMATITIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; EARLY INTERVENTION; ENTHESITIS; FUNCTIONAL STATUS; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATORY BOWEL DISEASE; NAIL DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; SPONDYLITIS; TH17 CELL; TREATMENT RESPONSE; ARTHRITIS, PSORIATIC; PROCEDURES;

ARTHRITIS, PSORIATIC; BIOLOGICAL THERAPY; HUMANS;

EID: 84945443727     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.07.010     Document Type: Review

References (62)

1. Mease P.J., Armstrong A.W. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014, 74(4):423-441.
2. Acosta Felquer M.L., Coates L.C., Soriano E.R., et al. Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol 2014, 41(11):2277-2285.
3. Ritchlin C.T., Kavanaugh A., Mease P.J., et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009, 68(9):1387-1394.
4. Gossec L., Smolen J.S., Gaujoux-Viala C., et al. European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012, 71(1):4-12.
5. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356(9227):385-390.
6. Mease P.J., Kivitz A.J., Burch F.X., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50(7):2264-2272.
7. Sterry W., Ortonne J.P., Kirkham B., et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010, 340:c147.
8. Fagerli K.M., Lie E., van der Heijde D., et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014, 73(1):132-137.
9. Antoni C., Krueger G.G., de Vlam K., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64(8):1150-1157.
10. Mease P.J., Gladman D.D., Ritchlin C.T., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52(10):3279-3289.
11. Mease P.J., Ory P., Sharp J.T., et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009, 68(5):702-709.
12. Vogelzang E.H., Kneepkens E.L., Nurmohamed M.T., et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis 2014, 73(12):2178-2182.
13. Kavanaugh A., McInnes I., Mease P., et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009, 60(4):976-986.
14. Kavanaugh A., van der Heijde D., Beutler A., et al. Patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy demonstrate less radiographic progression: Results through 5 years of the randomized, placebo-controlled, GO-REVEAL study. Arthritis Care Res (Hoboken) 2015, [Epub ahead of print].
15. Smolen J.S., Kay J., Doyle M.K., et al. Golimumab in Patients with Active Rheumatoid Arthritis After Treatment with Tumour Necrosis Factor Alpha Inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374(9685):210-221.
16. Mease P.J., Fleischmann R., Deodhar A.A., et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014, 73(1):48-55.
17. Mease P., Genovese M.C., Gladstein G., et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011, 63(4):939-948.
18. Fonseca J.E., Santos M.J., Canhao H., et al. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009, 8(7):538-542.
19. Costa L., Caso F., Cantarini L., et al. Efficacy of tocilizumab in a patient with refractory psoriatic arthritis. Clin Rheumatol 2014, 33(9):1355-1357.
20. Mease P., Strand V., Shalamberidze L., et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012, 71(7):1183-1189.
21. Mease P.J., Gottlieb A., Berman A., et al. A phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to evaluate the efficacy and safety of clazakizumab, an anti-IL-6 monoclonal antibody, in adults with active psoriatic arthritis. Arthritis Rheum 2014, 66(S10):S423. [abstract: 952].
22. Celis R., Planell N., Fernandez-Sueiro J.L., et al. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther 2012, 14(2):R93.
23. Mease P.J. Is there a role for rituximab in the treatment of spondyloarthritis and psoriatic arthritis?. J Rheumatol 2012, 39(12):2235-2237.
24. Mease P., Kavanaugh A., Genovese M., et al. Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions. Arthritis Rheum 2010, 62(10 (Supp)):S818.
25. Rouvier E., Luciani M.F., Mattei M.G., et al. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993, 150(12):5445-5456.
26. van den Berg W.B., McInnes I.B. Th17 cells and IL-17 a-focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013, 43(2):158-170.
27. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361(9):888-898.
28. Frleta M., Siebert S., McInnes I.B. The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Curr Rheumatol Rep 2014, 16(4):414.
29. Sherlock J.P., Joyce-Shaikh B., Turner S.P., et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012, 18(7):1069-1076.
30. Lories R.J., McInnes I.B. Primed for inflammation: enthesis-resident T cells. Nat Med 2012, 18(7):1018-1019.
31. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med 2009, 361(5):496-509.
32. Raychaudhuri S.P. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013, 44(2):183-193.
33. Jandus C., Bioley G., Rivals J.P., et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008, 58(8):2307-2317.
34. Suzuki E., Mellins E.D., Gershwin M.E., et al. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 2014, 13(4-5):496-502.
35. Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371(9625):1665-1674.
36. Papp K.A., Langley R.G., Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371(9625):1675-1684.
37. McInnes I.B., Kavanaugh A., Gottlieb A.B., et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013, 382(9894):780-789.
38. Ritchlin C., Rahman P., Kavanaugh A., et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014, 73(6):990-999.
39. Kavanaugh A., Ritchlin C., Rahman P., et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014, 73(6):1000-1006.
40. Podubbnyy D., Callhoff J., Listing J., et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Arthritis Rheum 2013, 65(10 (Suppl)):S766.
41. Langley R.G., Elewski B.E., Lebwohl M., et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014, 371(4):326-338.
42. Mease P., McInnes I., Kirkham B., et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 2014, 66(S10):S423.
43. van der Heijde D., Landewe R., Mease P., et al. Secukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled study. Arthritis Rheum 2014, 66(S10):S424.
44. McInnes I.B., Mease P.J., Kirkham B., et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015, [Epub ahead of print].
45. Baeten D., Braun J., Baraliakos X., et al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing. Arthritis Rheum 2014, 66(S10):S360.
46. Sieper J., Braun J., Baraliakos X., et al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a phase 3, randomized, placebo-controlled trial with subcutaneous loading and maintenance dosing. Arthritis Rheum 2014, 66(10 (Suppl)):S232.
47. Leonardi C., Matheson R., Zachariae C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366(13):1190-1199.
48. Genovese M.C., Greenwald M., Cho C.S., et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheum 2014, 66(7):1693-1704.
49. Papp K.A., Leonardi C., Menter A., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366(13):1181-1189.
50. Mease P.J., Genovese M.C., Greenwald M.W., et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014, 370(24):2295-2306.
51. Martin D.A., Churchill M., Flores-Suarez L., et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013, 15(5):R164.
52. Pavelka K., Chon Y., Newmark R., et al. A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheum 2012, 64(S362). [abstract: 831].
53. Sofen H., Smith S., Matheson R.T., et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014, 133(4):1032-1040.
54. Tausend W., Downing C., Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg 2014, 18(3):156-169.
55. Leonardi C.L., Gordon K.B. New and emerging therapies in psoriasis. Semin Cutan Med Surg 2014, 33(2 Suppl 2):S37-41.
56. Baranauskaite A., Raffayova H., Kungurov N.V., et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 2012, 71(4):541-548.
57. Mease P., Collier D., Karki N., et al. Persistence and predictors of biologic TNFi therapy among biologic naïve psoriatic arthritis patients in a US registry. Arthritis Rheum 2014, 66(S10). [abstract: 1853].
58. Smolen J.S., Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003, 2(6):473-488.
59. Smolen J., Breedveld F., Burmester G., et al. Extended report: treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2015, [Epub ahead of print].
60. Smolen J.S., Braun J., Dougados M., et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014, 73(1):6-16.
61. Coates L., Moberley A., McParland L., et al. Results of a randomised, controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control improves outcome. Arthritis Rheum 2013, 65(Supp 10):814.
62. Coates L.C., Fransen J., Helliwell P.S. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2009, 69(1):48-53.